Latest news with #GregoryWilliams
Reuters
4 days ago
- Business
- Reuters
US judge overturns Amgen's $50.3 mln loss in cancer drug patent case
Aug 14 (Reuters) - Amgen (AMGN.O), opens new tab convinced a federal judge in Delaware on Thursday to invalidate two patents owned by Lindis Biotech, undercutting a $50.3 million jury verdict Lindis won last year in an infringement lawsuit over Amgen's leukemia drug Blincyto. U.S. District Judge Gregory Williams said in a court order, opens new tab that the patents were unenforceable due to their inventor's "inequitable conduct" at the U.S. Patent and Trademark Office. Williams' opinion outlining his reasoning for the decision was filed under seal. Attorneys and spokespeople for the companies did not immediately respond to requests for comment on the ruling. Germany-based Lindis sued Amgen in 2022, alleging that Blincyto infringed patents related to reducing the side effects of using antibodies to stimulate the body's immune system to kill cancer cells. Thousand Oaks, California-based Amgen earned $800 million from U.S. sales of Blincyto last year, according to a company report. A Delaware jury determined in December that Amgen owed at least $50.3 million for infringing Lindis' patents. The jury also said that the infringement was willful, which could have led the court to increase the award up to three times the amount. Amgen argued that the patents were invalid because their inventor submitted false information in his patent application. Williams held a separate bench trial in January on Amgen's defense. The case is Lindis Biotech GmbH v. Amgen Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00035. For Amgen: Michael Wise, Joseph Hamilton, Lara Dueppen, Courtney Prochnow and Alisha Burgin of Perkins Coie; Lisa Pensabene, Hassen Sayeed, Carolyn Wall, Luann Simmons and Sorin Zaharia of O'Melveny & Myers For Lindis: James Taylor, Jessica Jones, Henry Platt, Robert Gill and Matthew Antonelli of Saul Ewing Read more: Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit
Yahoo
10-08-2025
- Business
- Yahoo
TD Cowen Backs Comcast (CMCSA) on Strong Q2 and Diversified Growth
Comcast Corp. (NASDAQ:CMCSA) is one of the best defensive stocks to invest in according to analysts. On August 1, TD Cowen analyst Gregory Williams reiterated his Buy rating on Comcast and raised the price target to $46 from $45, following the company's better-than-expected second-quarter results. Williams pointed to solid, better-than-expected performance across key metrics, including EBITDA, free cash flow, and mobile subscriber growth. He noted that Comcast's broadband business is starting to show signs of stability, with improving trends in subscriber connections and churn, even as competition remains intense. An aerial view of a broadcasting company's television stations, showing the power of the company's media presence. Comcast's growth is being driven by several business lines. Its broadband and mobile segments continue to perform well, and its streaming operations are making meaningful contributions. The analyst believes that these areas give the company multiple paths to sustain revenue growth over the coming years. The analyst also highlighted Comcast's strong financial footing. Among the most notable financial health metrics highlighted were the company's healthy balance sheet, ongoing share repurchases, consistent dividend payouts, and expected tax-related benefits. Although it's still early to gauge the full impact of Comcast's recent strategic initiatives, Williams sees the initial results as encouraging. In addition, the combination of operational momentum and sound financial management supports his positive outlook on the stock. Comcast Corp. (NASDAQ:CMCSA) is a global media and technology company that delivers broadband, wireless, video, and voice services, distributes and streams entertainment, sports, and news, and operates Universal theme parks. While we acknowledge the potential of CMCSA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and . Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
12-07-2025
- Business
- Business Insider
Echostar (SATS) Gets a Buy from TD Cowen
TD Cowen analyst Gregory Williams assigned a Buy rating to Echostar on July 8 and set a price target of $28.00. The company's shares closed today at $30.86. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Williams is an analyst with an average return of -2.2% and a 45.81% success rate. Williams covers the Communication Services sector, focusing on stocks such as AT&T, Charter Communications, and T Mobile US. Echostar has an analyst consensus of Moderate Buy, with a price target consensus of $29.70. The company has a one-year high of $33.04 and a one-year low of $14.79. Currently, Echostar has an average volume of 3.67M.
Business Insider
12-07-2025
- Business
- Business Insider
TD Cowen Sticks to Its Buy Rating for Altice Usa (ATUS)
In a report released on July 7, Gregory Williams from TD Cowen maintained a Buy rating on Altice Usa, with a price target of $4.00. The company's shares closed today at $2.57. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Williams covers the Communication Services sector, focusing on stocks such as AT&T, Charter Communications, and T Mobile US. According to TipRanks, Williams has an average return of -2.2% and a 45.81% success rate on recommended stocks. In addition to TD Cowen, Altice Usa also received a Buy from Raymond James's Frank Louthan in a report issued on July 9. However, on July 2, Bank of America Securities maintained a Sell rating on Altice Usa (NYSE: ATUS). Based on Altice Usa's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.15 billion and a GAAP net loss of $75.68 million. In comparison, last year the company earned a revenue of $2.25 billion and had a GAAP net loss of $21.19 million
Business Insider
12-07-2025
- Business
- Business Insider
Charter Communications (CHTR) Receives a Buy from TD Cowen
TD Cowen analyst Gregory Williams maintained a Buy rating on Charter Communications on July 7 and set a price target of $520.00. The company's shares closed today at $392.17. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Williams is an analyst with an average return of -2.2% and a 45.81% success rate. Williams covers the Communication Services sector, focusing on stocks such as AT&T, Charter Communications, and T Mobile US. In addition to TD Cowen, Charter Communications also received a Buy from Bank of America Securities's Jessica Reif Ehrlich in a report issued on July 1. However, on July 7, RBC Capital maintained a Hold rating on Charter Communications (NASDAQ: CHTR).
